<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7372203\results\search\disease\results.xml">
  <result pre="Arizona State University, [2], grid.266093.80000 0001 0668 7243Division of Nephrology," exact="Hypertension" post="and Kidney Transplantation, University of California, Irvine, School of"/>
  <result pre="University, [2], grid.266093.80000 0001 0668 7243Division of Nephrology, Hypertension and" exact="Kidney" post="Transplantation, University of California, Irvine, School of Medicine, [3],"/>
  <result pre="and Harvard Medical School, [6], grid.240416.50000 0004 0608 1972John Ochsner" exact="Heart" post="and Vascular Institute, Ochsner Clinical School-The University of Queensland"/>
  <result pre="Medical School, [6], grid.240416.50000 0004 0608 1972John Ochsner Heart and" exact="Vascular" post="Institute, Ochsner Clinical School-The University of Queensland School of"/>
  <result pre="of Medicine, [7], grid.411654.30000 0004 0581 3406Department of Family Medicine," exact="American" post="University of Beirut Medical Center, [8], grid.266093.80000 0001 0668"/>
  <result pre="of Beirut Medical Center, [8], grid.266093.80000 0001 0668 7243Division of" exact="Infectious" post="Diseases, Department of Medicine, University of California, Irvine, School"/>
  <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
  <result pre="declaration of COVID-19 as a global pandemic. Abstract The severe" exact="acute" post="respiratory syndrome coronavirus 2 associated coronavirus disease 2019 (COVID-19)"/>
  <result pre="of COVID-19 as a global pandemic. Abstract The severe acute" exact="respiratory" post="syndrome coronavirus 2 associated coronavirus disease 2019 (COVID-19) illness"/>
  <result pre="COVID-19 as a global pandemic. Abstract The severe acute respiratory" exact="syndrome" post="coronavirus 2 associated coronavirus disease 2019 (COVID-19) illness is"/>
  <result pre="Abstract The severe acute respiratory syndrome coronavirus 2 associated coronavirus" exact="disease" post="2019 (COVID-19) illness is a syndrome of viral replication"/>
  <result pre="coronavirus 2 associated coronavirus disease 2019 (COVID-19) illness is a" exact="syndrome" post="of viral replication in concert with a host inflammatory"/>
  <result pre="associated coronavirus disease 2019 (COVID-19) illness is a syndrome of" exact="viral" post="replication in concert with a host inflammatory response. The"/>
  <result pre="concert with a host inflammatory response. The cytokine storm and" exact="viral" post="evasion of cellular immune responses may play an equally"/>
  <result pre="role in the pathogenesis, clinical manifestation, and outcomes of COVID-19." exact="Systemic" post="proinflammatory cytokines and biomarkers are elevated as the disease"/>
  <result pre="COVID-19. Systemic proinflammatory cytokines and biomarkers are elevated as the" exact="disease" post="progresses towards its advanced stages, and correlate with worse"/>
  <result pre="the search terms â€˜coronavirusâ€™, â€˜immunologyâ€™, â€˜cytokine stormâ€™, â€˜immunomodulatorsâ€™, â€˜pharmacologyâ€™, â€˜severe" exact="acute" post="respiratory syndrome 2â€™, â€˜SARS-CoV-2â€™, and â€˜COVID-19â€™. Specific immune modulators"/>
  <result pre="search terms â€˜coronavirusâ€™, â€˜immunologyâ€™, â€˜cytokine stormâ€™, â€˜immunomodulatorsâ€™, â€˜pharmacologyâ€™, â€˜severe acute" exact="respiratory" post="syndrome 2â€™, â€˜SARS-CoV-2â€™, and â€˜COVID-19â€™. Specific immune modulators include"/>
  <result pre="terms â€˜coronavirusâ€™, â€˜immunologyâ€™, â€˜cytokine stormâ€™, â€˜immunomodulatorsâ€™, â€˜pharmacologyâ€™, â€˜severe acute respiratory" exact="syndrome" post="2â€™, â€˜SARS-CoV-2â€™, and â€˜COVID-19â€™. Specific immune modulators include anti-cytokines"/>
  <result pre="on survival and clinical symptoms. Key Points COVID-19 is a" exact="syndrome" post="of viral replication and a host inflammatory response. Tackling"/>
  <result pre="and clinical symptoms. Key Points COVID-19 is a syndrome of" exact="viral" post="replication and a host inflammatory response. Tackling the immune"/>
  <result pre="Tackling the immune response may be as important as addressing" exact="viral" post="replication. Specific and non-specific immune modulators have the potential"/>
  <result pre="storm. Introduction Although the pathogenesis of COVID-19, the result of" exact="infection" post="with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is"/>
  <result pre="the pathogenesis of COVID-19, the result of infection with severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), is still not completely"/>
  <result pre="pathogenesis of COVID-19, the result of infection with severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), is still not completely understood,"/>
  <result pre="of COVID-19, the result of infection with severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), is still not completely understood, a"/>
  <result pre="2]. Stage I (early infection) begins at the time of" exact="viral" post="inoculation and establishment of infection. Patients may or may"/>
  <result pre="is characterized by hyperresponsiveness of the immune system. Patients develop" exact="viral pneumonia" post="and possibly hypoxia, and markers of systemic inflammation are"/>
  <result pre="characterized by hyperresponsiveness of the immune system. Patients develop viral" exact="pneumonia" post="and possibly hypoxia, and markers of systemic inflammation are"/>
  <result pre="Patients develop viral pneumonia and possibly hypoxia, and markers of" exact="systemic" post="inflammation are elevated. The third stage is characterized by"/>
  <result pre="third stage is characterized by a hypercoagulable state. Patients with" exact="hypoxia" post="are likely to progress to stage IV, the most"/>
  <result pre="severe stage, where multiorgan failure occurs. Most patients also develop" exact="lymphopenia" post="and pneumonia with bilateral infiltrations on chest computed tomography"/>
  <result pre="where multiorgan failure occurs. Most patients also develop lymphopenia and" exact="pneumonia" post="with bilateral infiltrations on chest computed tomography (CT) scan"/>
  <result pre="failure occurs. Most patients also develop lymphopenia and pneumonia with" exact="bilateral" post="infiltrations on chest computed tomography (CT) scan [3â€&quot;5]. Systemic"/>
  <result pre="patients also develop lymphopenia and pneumonia with bilateral infiltrations on" exact="chest" post="computed tomography (CT) scan [3â€&quot;5]. Systemic proinflammatory cytokines and"/>
  <result pre="with bilateral infiltrations on chest computed tomography (CT) scan [3â€&quot;5]." exact="Systemic" post="proinflammatory cytokines and biomarkers such as interleukin (IL)-1, IL-2,"/>
  <result pre="and biomarkers such as interleukin (IL)-1, IL-2, IL-6, and IL-7," exact="tumor" post="necrosis factor (TNF)-Î±, granulocyteâ€&quot;macrophage colony-stimulating factor (GM-CSF), macrophage inflammatory"/>
  <result pre="The presence of elevated proinflammatory cytokines in advanced stages of" exact="disease" post="was also observed in prior epidemics, such as those"/>
  <result pre="those caused by SARS-CoV and MERS-CoV, suggesting a cytokine release" exact="syndrome" post="(CRS) or â€˜cytokine stormâ€™-mediatedÂ immunopathology [7â€&quot;9]. The cytokine dysregulation"/>
  <result pre="lead to lung infiltration and critical symptoms, including sepsis, shock," exact="respiratory" post="failure, acute respiratory distress syndrome (ARDS), multiorgan system dysfunction,"/>
  <result pre="lung infiltration and critical symptoms, including sepsis, shock, respiratory failure," exact="acute" post="respiratory distress syndrome (ARDS), multiorgan system dysfunction, and death"/>
  <result pre="infiltration and critical symptoms, including sepsis, shock, respiratory failure, acute" exact="respiratory" post="distress syndrome (ARDS), multiorgan system dysfunction, and death [10]."/>
  <result pre="critical symptoms, including sepsis, shock, respiratory failure, acute respiratory distress" exact="syndrome" post="(ARDS), multiorgan system dysfunction, and death [10]. Since lymphopenia"/>
  <result pre="distress syndrome (ARDS), multiorgan system dysfunction, and death [10]. Since" exact="lymphopenia" post="is often observed in early and late stages of"/>
  <result pre="T cells [9]. The cytokine storm is thought to resemble" exact="secondary" post="hemophagocytic lymph histiocytosis (sHLH) [11]. The macrophage activation syndrome"/>
  <result pre="The cytokine storm is thought to resemble secondary hemophagocytic lymph" exact="histiocytosis" post="(sHLH) [11]. The macrophage activation syndrome (MAS)-like pulmonary immunopathology"/>
  <result pre="resemble secondary hemophagocytic lymph histiocytosis (sHLH) [11]. The macrophage activation" exact="syndrome" post="(MAS)-like pulmonary immunopathology characteristic of COVID-19, above and beyond"/>
  <result pre="hemophagocytic lymph histiocytosis (sHLH) [11]. The macrophage activation syndrome (MAS)-like" exact="pulmonary" post="immunopathology characteristic of COVID-19, above and beyond the direct"/>
  <result pre="findings in this patient population [12]. Cytokine storm, along with" exact="viral" post="evasion of cellular immune responses, may play an equally"/>
  <result pre="cellular immune responses, may play an equally important role in" exact="disease" post="progression. Thus, tackling the immune response with immunomodulatory agents"/>
  <result pre="response with immunomodulatory agents may be as important as addressing" exact="viral" post="replication to prevent the progression to multiorgan dysfunction (Fig.Â"/>
  <result pre="harm. Whether such agents are beneficial in other stages of" exact="infection" post="remains a matter of study. Â Created with biorender.com."/>
  <result pre="of transcription, MIP-1Î± macrophage inflammatory protein 1-Î±, MyD88 myeloid differentiation" exact="primary" post="response 88, NF-ÎºB nuclear factor-ÎºB, RAAS reninâ€&quot;angiotensinâ€&quot;aldosterone system, rhuGM-CSF"/>
  <result pre="colony-stimulating factor, sIL-6R soluble IL-6Â receptor, TLR toll-like receptor, TNF" exact="tumor" post="necrosis factor reserve Methods of Literature Review An English-language"/>
  <result pre="Search terms included â€˜coronavirusâ€™, â€˜immunologyâ€™, â€˜cytokine stormâ€™, â€˜immunomodulatorsâ€™, â€˜pharmacologyâ€™, â€˜severe" exact="acute" post="respiratory syndrome 2â€™, â€˜SARS-CoV-2â€™, and â€˜COVID-19â€™. The authors of"/>
  <result pre="terms included â€˜coronavirusâ€™, â€˜immunologyâ€™, â€˜cytokine stormâ€™, â€˜immunomodulatorsâ€™, â€˜pharmacologyâ€™, â€˜severe acute" exact="respiratory" post="syndrome 2â€™, â€˜SARS-CoV-2â€™, and â€˜COVID-19â€™. The authors of this"/>
  <result pre="included â€˜coronavirusâ€™, â€˜immunologyâ€™, â€˜cytokine stormâ€™, â€˜immunomodulatorsâ€™, â€˜pharmacologyâ€™, â€˜severe acute respiratory" exact="syndrome" post="2â€™, â€˜SARS-CoV-2â€™, and â€˜COVID-19â€™. The authors of this current"/>
  <result pre="T cells, develops later and contributes to both clearing of" exact="infection" post="and immunity against subsequent infection. Innate and adaptive immunity"/>
  <result pre="Immunostimulators are often prescribed to enhance the immune response against" exact="infectious" post="diseases,Â however, morbidity and mortality in severe COVID-19 is"/>
  <result pre="reninâ€&quot;angiotensinâ€&quot;aldosterone system inhibitors, rhuGM-CSF recombinant human granulocyteâ€&quot;macrophage colony-stimulating factor, TNF" exact="tumor" post="necrosis factor Specific Immune Modulators Anti-cytokines Interleukin (IL)-1 Receptor"/>
  <result pre="Anakinra is a recombinant human IL-1 receptor antagonist indicated for" exact="rheumatoid arthritis" post="(RA) and cryopyrin-associated periodic syndromes [16]. It works by"/>
  <result pre="is a recombinant human IL-1 receptor antagonist indicated for rheumatoid" exact="arthritis" post="(RA) and cryopyrin-associated periodic syndromes [16]. It works by"/>
  <result pre="IL-1 receptor antagonist indicated for rheumatoid arthritis (RA) and cryopyrin-associated" exact="periodic" post="syndromes [16]. It works by inhibiting the proinflammatory cytokines"/>
  <result pre="hemophagocytosis score (HScore) and diagnosed sHLH [22]. The mortality was" exact="lower" post="than previous series of patients with sHLH in sepsis,"/>
  <result pre="anakinra was associated with less need for vasopressors, significantly improved" exact="pulmonary" post="function, and lower HScore. A phase III, randomized, open-label,"/>
  <result pre="with less need for vasopressors, significantly improved pulmonary function, and" exact="lower" post="HScore. A phase III, randomized, open-label, multicenter trial (NCT04324021)"/>
  <result pre="emapalumab, an anti-interferon (IFN)-Î³ antibody, in the treatment of hyperinflammatory" exact="syndrome" post="caused by the cytokine storm commenced on 2 April"/>
  <result pre="are an indicator of poor outcome in COVID-19 patients with" exact="pneumonia" post="and ARDS [23]. Tocilizumab (ActemraÂ®) is a recombinant humanized"/>
  <result pre="FDA-approved for the management of RA, giant cell arthritis, polyarticular" exact="juvenile idiopathic arthritis," post="and systemic juvenile idiopathic arthritis [24]. It is also"/>
  <result pre="of RA, giant cell arthritis, polyarticular juvenile idiopathic arthritis, and" exact="systemic" post="juvenile idiopathic arthritis [24]. It is also approved for"/>
  <result pre="RA, giant cell arthritis, polyarticular juvenile idiopathic arthritis, and systemic" exact="juvenile idiopathic arthritis" post="[24]. It is also approved for the management of"/>
  <result pre="cell arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic" exact="arthritis" post="[24]. It is also approved for the management of"/>
  <result pre="patients. Five patients received two or more doses of tocilizumab." exact="Elevated" post="CRP levels rapidly decreased in all patients following administration,"/>
  <result pre="observational Italian study of 20 renal transplant recipients with SARS-CoV-2" exact="pneumonia" post="included six patients who received tocilizumab. Three (50%) of"/>
  <result pre="death (adjusted HR 0.61, 95% CI 0.40â€&quot;0.92, pâ€‰=â€‰0.020) [27]. The" exact="primary" post="outcome was a composite of death or progression to"/>
  <result pre="CI 16.2â€&quot;29.0) of the patients who received tocilizumab had the" exact="primary" post="outcome, compared with 36.5% (95% CI 30.7â€&quot;42.2) in those"/>
  <result pre="open-label, phase II, randomized clinical trial, showed that a significantly" exact="lower" post="number of the patients in the tocilizumab arm achieved"/>
  <result pre="number of the patients in the tocilizumab arm achieved the" exact="primary" post="outcome of need for ventilation, or death, at day"/>
  <result pre="Another IL-6 receptor antagonist that may potentially combat CRS and" exact="pulmonary" post="symptoms in severely ill patients is sarilumab (KefzaraÂ®), which"/>
  <result pre="is sarilumab (KefzaraÂ®), which is indicated for the treatment of" exact="adult" post="patients with moderately to severely active RA who have"/>
  <result pre="protein kinases. It is indicated for intermediate- or high-risk myelofibrosis," exact="polycythemia vera," post="and steroid-refractory acute graft-versus-host disease [33]. Ruxolitinib interrupts signaling"/>
  <result pre="indicated for intermediate- or high-risk myelofibrosis, polycythemia vera, and steroid-refractory" exact="acute" post="graft-versus-host disease [33]. Ruxolitinib interrupts signaling downstream of multiple"/>
  <result pre="intermediate- or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host" exact="disease" post="[33]. Ruxolitinib interrupts signaling downstream of multiple proinflammatory cytokines,"/>
  <result pre="COVID-19 patients, and required drug discontinuation [35]. Both patients developed" exact="cutaneous" post="reactions with purpuras and a progressive decrease in hematocrit"/>
  <result pre="progressive decrease in hematocrit values, and one patient also developed" exact="thrombocytopenia" post="and a deep-tissue infection. These adverse events may be"/>
  <result pre="plus standard of care, compared with standard-of-care therapy alone, in" exact="adult" post="patients with COVID-19-associated cytokine storm (NCT04362137; RUXOCOVID), and in"/>
  <result pre="is predicted to have a dual effect of reducing both" exact="viral" post="entry and inflammation in COVID-19 patients [36]. Baricitinib might"/>
  <result pre="an Italian open-label study of 12 patients with moderate COVID-19" exact="pneumonia" post="[40], baricitinib therapy combined with lopinavir/ritonavir was associated with"/>
  <result pre="patients required intensive care unit support, however, the study was" exact="limited" post="by its small sample size and open-label design. An"/>
  <result pre="as an arm in the National Institute of Allergy and" exact="Infectious" post="Diseasesâ€™ (NIAID) phase III adaptive COVID-19 treatment trial [41]."/>
  <result pre="Treatment Trial. This combination may be able to control the" exact="viral infection" post="as well as reduce the immune system reaction. Anti-tumor"/>
  <result pre="Trial. This combination may be able to control the viral" exact="infection" post="as well as reduce the immune system reaction. Anti-tumor"/>
  <result pre="Necrosis Factor-Î± TNFÎ± plays a key role in almost all" exact="acute" post="inflammatory reactions by inducing oxidative stress and inflammation. TNFÎ±"/>
  <result pre="TNFÎ±-converting enzyme (TACE)-dependent shedding of the ACE2 ectodomain, which facilitates" exact="viral" post="entry and causes tissue damage through TNFÎ± production [47]."/>
  <result pre="adalimumab or infliximab, is used in the management of several" exact="autoimmune" post="inflammatory diseases such as RA, inflammatory bowel disease, and"/>
  <result pre="the management of several autoimmune inflammatory diseases such as RA," exact="inflammatory bowel disease," post="and ankylosing spondylitis [48]. Experimental studies suggest a potential"/>
  <result pre="management of several autoimmune inflammatory diseases such as RA, inflammatory" exact="bowel" post="disease, and ankylosing spondylitis [48]. Experimental studies suggest a"/>
  <result pre="autoimmune inflammatory diseases such as RA, inflammatory bowel disease, and" exact="ankylosing spondylitis" post="[48]. Experimental studies suggest a potential rationale for use"/>
  <result pre="inflammatory diseases such as RA, inflammatory bowel disease, and ankylosing" exact="spondylitis" post="[48]. Experimental studies suggest a potential rationale for use"/>
  <result pre="suggest a potential rationale for use of anti-TNF therapy in" exact="viral pneumonia" post="[46]. It has been proposed that a single infusion"/>
  <result pre="a potential rationale for use of anti-TNF therapy in viral" exact="pneumonia" post="[46]. It has been proposed that a single infusion"/>
  <result pre="also concern that anti-TNFÎ± therapy might increase the risk of" exact="bacterial" post="or fungal superinfections [49]. Their effectiveness, wide availability, various"/>
  <result pre="more advanced stages. A Chinese study evaluating adalimumab in COVID-19" exact="infection" post="is underway (ChiCTR2000030089). A prospective, single center, phase II"/>
  <result pre="trial evaluating the efficacy of infliximab or infliximab-abda in hospitalized" exact="adult" post="patients with severe or critical COVID-19 has also commenced"/>
  <result pre="growth factor and proinflammatory cytokine that is released from alveolar" exact="epithelial" post="cells and has been shown to drive pulmonary host"/>
  <result pre="from alveolar epithelial cells and has been shown to drive" exact="pulmonary" post="host defense function against pathogens, including the influenza virus"/>
  <result pre="and differentiation of macrophages and dendritic cells [52], GM-CSF stimulates" exact="epithelial" post="repair, including epithelial proliferation and barrier restoration, through direct"/>
  <result pre="macrophages and dendritic cells [52], GM-CSF stimulates epithelial repair, including" exact="epithelial" post="proliferation and barrier restoration, through direct interaction with the"/>
  <result pre="proliferation and barrier restoration, through direct interaction with the alveolar" exact="epithelial" post="cells, thereby providing a lung-protective effect [51]. In patients"/>
  <result pre="lavage fluid (BALF) are associated with antiapoptotic effects and improved" exact="epithelial" post="barrier integrity and survival [53, 54]. Studies have shown"/>
  <result pre="benefit to COVID-19 patients by providing the stimulus to restore" exact="pulmonary" post="hemostasis and repair [57]. Previous studies have shown that"/>
  <result pre="shown that a low-dose of intravenous GM-CSF in severely septic" exact="adult" post="patients with respiratory dysfunction improves oxygenation and gas exchange"/>
  <result pre="low-dose of intravenous GM-CSF in severely septic adult patients with" exact="respiratory" post="dysfunction improves oxygenation and gas exchange [58], although it"/>
  <result pre="although it failed to improve survival and ventilation parameters in" exact="adult" post="patients with acute lung injury in another trial [57]."/>
  <result pre="to improve survival and ventilation parameters in adult patients with" exact="acute" post="lung injury in another trial [57]. There is evidence"/>
  <result pre="an adjuvant therapy for the management of COVID-19 associated with" exact="acute" post="hypoxic respiratory failure and ARDS (NCT04326920). Patients will be"/>
  <result pre="therapy for the management of COVID-19 associated with acute hypoxic" exact="respiratory" post="failure and ARDS (NCT04326920). Patients will be randomized to"/>
  <result pre="in the alveoli should be achieved for virus clearance and" exact="acute" post="lung injury, as well as ARDS treatment [52], it"/>
  <result pre="convalescent plasma transfusion from patients who have recovered from the" exact="infection" post="with a high neutralizing antibody titer (NAT) may provide"/>
  <result pre="passive immunity that could be beneficial in the prevention of" exact="infection" post="or as a treatment strategy for patients with COVID-19"/>
  <result pre="In a study of 93 patients with severe H1N1 2009" exact="infection" post="requiring intensive care, 20 (21.5%) of whom received convalescent"/>
  <result pre="use of plasma was associated with a reduction in the" exact="viral" post="load on days 3, 5, and 7 (pâ€‰ pâ€‰"/>
  <result pre="better outcomes than those who received treatment later in the" exact="disease" post="course [63, 64, 69, 72]. Serious adverse events or"/>
  <result pre="and antiviral treatment [73]. Before transfusion, patients displayed continuously high" exact="viral" post="load despite antiviral treatment for at least 10Â days."/>
  <result pre="temperature of four patients normalized within 3Â days, Sequential Organ" exact="Failure" post="Assessment (SOFA) score decreased, PAO2/FIO2 increased within 12Â days,"/>
  <result pre="Failure Assessment (SOFA) score decreased, PAO2/FIO2 increased within 12Â days," exact="viral" post="loads decreased and became negative within 12Â days after"/>
  <result pre="COVID-19 symptoms, such as fever, cough, shortness of breath, and" exact="chest" post="pain improved in all patients within 1â€&quot;3Â days following"/>
  <result pre="days following transfusion. Patients showed variable degrees of improvement on" exact="chest" post="CT, where those transfused before 14Â days post onset"/>
  <result pre="manifested major adverse events such as transfusion-associated circulatory overload, transfusion-related" exact="acute" post="lung injury (TRALI), and severe allergic transfusion reaction, and"/>
  <result pre="plasma therapy on 103 COVID-19 patients with severe or life-threatening" exact="disease" post="found no significant difference in time to clinical improvement"/>
  <result pre="only observed in the subgroup of patients with severe COVID-19" exact="disease" post="(HR 2.15, 95% CI 1.07â€&quot;4.32, pâ€‰=â€‰0.03). However, most patients"/>
  <result pre="plasma [77]. IVIG has been used to provide immunity to" exact="viral" post="infections [78], including SARS, although the benefits of the"/>
  <result pre="[77]. IVIG has been used to provide immunity to viral" exact="infections" post="[78], including SARS, although the benefits of the treatment"/>
  <result pre="administration,Â normal body temperature was achieved in 1â€&quot;2Â days and" exact="respiratory" post="rate improved in 3â€&quot;5Â days. These results are in"/>
  <result pre="mortality between patients who received IVIG adjuvant therapy for COVID-19" exact="pneumonia" post="within 48Â h of admission compared with those who"/>
  <result pre="antifibrotic properties, which theoretically could have a role in suppressing" exact="lung inflammation," post="particularly in the advanced stages of the disease [86]."/>
  <result pre="suppressing lung inflammation, particularly in the advanced stages of the" exact="disease" post="[86]. The debate regarding the use of corticosteroidsÂ in"/>
  <result pre="preventing anÂ extended cytokine response and accelerating the resolution of" exact="pulmonary" post="and systemic inflammation in pneumonia [87]. Additionally, corticosteroids may"/>
  <result pre="extended cytokine response and accelerating the resolution of pulmonary and" exact="systemic" post="inflammation in pneumonia [87]. Additionally, corticosteroids may help improve"/>
  <result pre="and accelerating the resolution of pulmonary and systemic inflammation in" exact="pneumonia" post="[87]. Additionally, corticosteroids may help improve the dysregulated immune"/>
  <result pre="corticosteroids can inhibit immune response, reduce pathogen clearance, and provoke" exact="viral" post="replication [86, 90]. Thus, it might be reasonable to"/>
  <result pre="a low dose (â‰¤â€‰0.5â€&quot;1Â mg/kg/day of methylprednisolone or equivalent) and" exact="short" post="duration (â‰¤â€‰7Â days) are used [26, 85, 91, 92]."/>
  <result pre="Patients with SARS receiving corticosteroids reported adverse events such as" exact="avascular necrosis," post="psychosis, diabetes, and delayed viral clearance [78]. Influenza patients"/>
  <result pre="adverse events such as avascular necrosis, psychosis, diabetes, and delayed" exact="viral" post="clearance [78]. Influenza patients manifest a higher risk of"/>
  <result pre="[78]. Influenza patients manifest a higher risk of mortality and" exact="secondary" post="infections with corticosteroids [93]. In MERS patients, corticosteroids delayed"/>
  <result pre="Influenza patients manifest a higher risk of mortality and secondary" exact="infections" post="with corticosteroids [93]. In MERS patients, corticosteroids delayed lower"/>
  <result pre="secondary infections with corticosteroids [93]. In MERS patients, corticosteroids delayed" exact="lower" post="respiratory tract clearance of MERS-CoV, although no effect on"/>
  <result pre="infections with corticosteroids [93]. In MERS patients, corticosteroids delayed lower" exact="respiratory" post="tract clearance of MERS-CoV, although no effect on mortality"/>
  <result pre="shedding. Currently, the World Health Organization (WHO) and Centers for" exact="Disease" post="Control and PreventionÂ (CDC) do not recommend the routine"/>
  <result pre="and PreventionÂ (CDC) do not recommend the routine use of" exact="systemic" post="corticosteroids for treatment of viral pneumonia unless indicated for"/>
  <result pre="recommend the routine use of systemic corticosteroids for treatment of" exact="viral pneumonia" post="unless indicated for another reason, such as asthma or"/>
  <result pre="the routine use of systemic corticosteroids for treatment of viral" exact="pneumonia" post="unless indicated for another reason, such as asthma or"/>
  <result pre="of viral pneumonia unless indicated for another reason, such as" exact="asthma" post="or chronic obstructive pulmonary disease exacerbation, or refractory septic"/>
  <result pre="viral pneumonia unless indicated for another reason, such as asthma" exact="or chronic" post="obstructive pulmonary disease exacerbation, or refractory septic shock [95,"/>
  <result pre="pneumonia unless indicated for another reason, such as asthma or" exact="chronic" post="obstructive pulmonary disease exacerbation, or refractory septic shock [95,"/>
  <result pre="indicated for another reason, such as asthma or chronic obstructive" exact="pulmonary" post="disease exacerbation, or refractory septic shock [95, 96]. The"/>
  <result pre="for another reason, such as asthma or chronic obstructive pulmonary" exact="disease" post="exacerbation, or refractory septic shock [95, 96]. The Surviving"/>
  <result pre="as asthma or chronic obstructive pulmonary disease exacerbation, or refractory" exact="septic shock" post="[95, 96]. The Surviving Sepsis Campaign COVID-19 subcommittee recommends"/>
  <result pre="Sepsis Campaign COVID-19 subcommittee recommends against the routine use of" exact="systemic" post="corticosteroids in mechanically ventilated adults with COVID-19 and respiratory"/>
  <result pre="of systemic corticosteroids in mechanically ventilated adults with COVID-19 and" exact="respiratory" post="failure (without ARDS), although this is a weak and"/>
  <result pre="showed that dexamethasone reduces mortality among COVID-19 patients with severe" exact="respiratory" post="complications [97]. Low-dose dexamethasone (6Â mg once daily, orally"/>
  <result pre="was reported in patients with milder symptoms (i.e. not requiring" exact="respiratory" post="support). Prior to these findings, a multicenter, randomized controlled"/>
  <result pre="a multicenter, randomized, controlled, open-label trial (DEXA-COVID19) involving mechanically ventilated" exact="adult" post="patients with ARDS with confirmed COVID-19 infection has commenced"/>
  <result pre="involving mechanically ventilated adult patients with ARDS with confirmed COVID-19" exact="infection" post="has commenced (NCT04325061). Compared with methylprednisolone, dexamethasone has less"/>
  <result pre="al. showed that in 46 patients with confirmed severe COVID-19" exact="pneumonia" post="that progressed to acute respiratory failure, the use of"/>
  <result pre="46 patients with confirmed severe COVID-19 pneumonia that progressed to" exact="acute" post="respiratory failure, the use of methylprednisolone 1â€&quot;2Â mg/kg daily"/>
  <result pre="patients with confirmed severe COVID-19 pneumonia that progressed to acute" exact="respiratory" post="failure, the use of methylprednisolone 1â€&quot;2Â mg/kg daily intravenously"/>
  <result pre="resolution (2.06â€‰Â±â€‰0.28 vs. 5.29â€‰Â±â€‰0.70; pâ€‰=â€‰0.010), faster improvement of SpO2, and" exact="lower" post="number of days on supplemental oxygenÂ therapy [8.2Â days"/>
  <result pre="IFNsÂ are cytokines that play a key factor inÂ reducingÂ" exact="viral" post="multiplication and modulating host immune response against viral infection"/>
  <result pre="inÂ reducingÂ viral multiplication and modulating host immune response against" exact="viral infection" post="[100]. They consist of the ubiquitous Î± and Î²"/>
  <result pre="reducingÂ viral multiplication and modulating host immune response against viral" exact="infection" post="[100]. They consist of the ubiquitous Î± and Î²"/>
  <result pre="subtypes. IFNsÂ are released by plasmacytoid dendritic cellsÂ during a" exact="viral infection" post="[100]. IFN treatment has been studied against MERS-CoV and"/>
  <result pre="IFNsÂ are released by plasmacytoid dendritic cellsÂ during a viral" exact="infection" post="[100]. IFN treatment has been studied against MERS-CoV and"/>
  <result pre="signaling, and immunomodulation [100]. IFNs also sensitize human cells to" exact="viral" post="proteins to prevent viral fusion or egress [100]. In"/>
  <result pre="IFNs also sensitize human cells to viral proteins to prevent" exact="viral" post="fusion or egress [100]. In vitroÂ studies suggest that"/>
  <result pre="beneficialÂ effect in patients with SARS [102]. A 2003 open-label," exact="uncontrolled" post="study of 22 SARS patients, 9 of whom received"/>
  <result pre="(e.g. NCT04354259, NCT04388709) and postexposure prophylaxis (e.g. NCT04344600) of SARS-CoV-2" exact="infection" post="are also underway. A multicenter, randomized, prospective study on"/>
  <result pre="underway. A multicenter, randomized, prospective study on pediatric patients with" exact="respiratory" post="syncytial virus investigated the use of nebulized INFÎ±-1b compared"/>
  <result pre="faster onset of action, a direct action on the mucosal" exact="epithelial" post="cells in the lungs, less systemic adverse effects, and"/>
  <result pre="action on the mucosal epithelial cells in the lungs, less" exact="systemic" post="adverse effects, and is less invasive to the pediatric"/>
  <result pre="a multicenter, prospective, open-label, randomized, phase II trial included 127" exact="adult" post="patients with COVID-19 who received triple antiviral therapy of"/>
  <result pre="that the triple antiviral therapy couldÂ shortenÂ theÂ duration of" exact="viral" post="shedding. Additionally, in a retrospective study of 77 hospitalized"/>
  <result pre="a retrospective study of 77 hospitalized adults with moderate COVID-19" exact="disease" post="who received aerosolized IFNÎ±-2b (5 million units twice daily;"/>
  <result pre="with those receiving umifenovir alone [107], however, the study was" exact="limited" post="by its small sample size, nonrandomized design, and dissimilar"/>
  <result pre="demographics and characteristics. Miscellaneous/Inadvertent Immunomodulators Statins Besides their role in" exact="cardiovascular" post="risk reduction, statins are reported to play a role"/>
  <result pre="protecting the innate immune response to COVID-19 [108]. The Massachusetts" exact="General" post="Hospital guide for critically ill patients with COVID-19 advocates"/>
  <result pre="addition, statins have direct beneficial effects that lead to decreased" exact="pulmonary" post="vascular injury and ultimately decreased lung injury [111]. However,"/>
  <result pre="statins have direct beneficial effects that lead to decreased pulmonary" exact="vascular" post="injury and ultimately decreased lung injury [111]. However, these"/>
  <result pre="and animal studies that are generally performed in response to" exact="bacterial infections," post="and these effects have not been validated in humans."/>
  <result pre="infections, and these effects have not been validated in humans." exact="Infection" post="with SARS-CoV results in increased induction of the myeloid"/>
  <result pre="with SARS-CoV results in increased induction of the myeloid differentiation" exact="primary" post="response 88 (MyD88) gene, which activates the nuclear factor"/>
  <result pre="inflammation and lung pathology and increased mouse survival after SARS-CoV" exact="infection" post="[113]. OverexpressionÂ orÂ underexpression of the MyD888 gene can"/>
  <result pre="underexpression of the MyD888 gene can increase the vulnerability to" exact="infection" post="and mortality from SARS-like coronaviruses [114, 115]. While statins"/>
  <result pre="the MyD88 pathway, they tend to preserve MyD88 levels during" exact="hypoxia" post="and under stress, which may confer a protective effect"/>
  <result pre="between statin use and asymptomatic status, defined as having no" exact="disease" post="symptoms in the entire study duration while testing positive"/>
  <result pre="therapy. However, if a COVID-19 patient does not have a" exact="cardiovascular" post="indication for a statin, it might not be reasonable"/>
  <result pre="to Ang II, is expressed near the surface of human" exact="epithelial" post="cells throughout the body, including the lungs [120]. ACE2"/>
  <result pre="inhibitor could reduce the severity of lung injury in some" exact="viral" post="pneumonias [122]. ACEi and ARB block the downstream effects"/>
  <result pre="II could be beneficial for preventing lung injury and improving" exact="systemic" post="health. Additionally, ACEi and ARB have a secondary effect"/>
  <result pre="and improving systemic health. Additionally, ACEi and ARB have a" exact="secondary" post="effect of increasing ACE2 expression. ACE2 catalyzes the conversion"/>
  <result pre="these patients tested positive for the virus. A history of" exact="hypertension" post="was described in 4357 patients (34.6%), of whom 2573"/>
  <result pre="was also no difference in the likelihood of severe COVID-19" exact="disease" post="between patients treated with an antihypertensive agent and untreated"/>
  <result pre="Italian population-based caseâ€&quot;control study of 6272 patients with confirmed SAR-CoV-2" exact="infection" post="revealed that there is no evidence that the use"/>
  <result pre="COVID-19, severity of the clinical manifestations, or the course of" exact="infection" post="[125]. While the use of an ACEi or ARB"/>
  <result pre="in controls, this was due to the higher prevalence of" exact="cardiovascular disease" post="in these patients. Both of these large studies demonstrated"/>
  <result pre="controls, this was due to the higher prevalence of cardiovascular" exact="disease" post="in these patients. Both of these large studies demonstrated"/>
  <result pre="and ARB is not associated with an increased risk of" exact="infection" post="with SARS-CoV-2. Thus, these agents should not be discontinued,"/>
  <result pre="provide antibacterial and potential immunomodulatory effects in the treatment of" exact="viral" post="respiratory tract infections, including influenza [133, 135], and other"/>
  <result pre="antibacterial and potential immunomodulatory effects in the treatment of viral" exact="respiratory" post="tract infections, including influenza [133, 135], and other respiratory"/>
  <result pre="viral respiratory tract infections, including influenza [133, 135], and other" exact="respiratory" post="conditions, such as ARDS [128, 129]. In a retrospective"/>
  <result pre="that theoretically may confer an anti-inflammatory response in patients with" exact="viral" post="infections [137â€&quot;140]. These drugs can reduce cytokine production, especially"/>
  <result pre="theoretically may confer an anti-inflammatory response in patients with viral" exact="infections" post="[137â€&quot;140]. These drugs can reduce cytokine production, especially IL-1"/>
  <result pre="and recovery of lymphopenia. Symptomatic patients with elevated CRP and/or" exact="lymphopenia" post="are the most likely COVID-19 patients to benefit from"/>
  <result pre="811 (58.9%) received hydroxychloroquine and 565 (41.1%) did not. The" exact="primary" post="endpoint was the time from study baseline to intubation"/>
  <result pre="the time from study baseline to intubation or death. The" exact="primary" post="endpoint developed in 346 patients (25.1%), and there was"/>
  <result pre="was no significant association between hydroxychloroquine use and the composite" exact="primary" post="endpoint (HR 1.04, 95% CI 0.82â€&quot;1.32). A multicentered, double-blind,"/>
  <result pre="with occupational or household exposure, 66% were healthcare workers. The" exact="primary" post="outcome was to identify new COVID-19 infections between patients"/>
  <result pre="healthcare workers. The primary outcome was to identify new COVID-19" exact="infections" post="between patients who received hydroxychloroquine or placebo. Within 4Â"/>
  <result pre="regimen of hydroxychloroquine or placebo. While there were slightly fewer" exact="infections" post="in the hydroxychloroquine arm (11.8% vs. 14.3%), the difference"/>
  <result pre="may imply that post-exposure prophylaxis is not effective in preventing" exact="symptomatic" post="infection among patients who are exposed to known COVID-19-positive"/>
  <result pre="imply that post-exposure prophylaxis is not effective in preventing symptomatic" exact="infection" post="among patients who are exposed to known COVID-19-positive infections."/>
  <result pre="drugs in COVID-19 patients [147]. Additionally, earlier observations of decreased" exact="viral" post="shedding with these drugs have not been consistently replicated."/>
  <result pre="that hydroxychloroquine did not provide a significant difference in the" exact="primary" post="endpoint of 28-day mortalityâ€&quot;25.7% in the hydroxychloroquine arm and"/>
  <result pre="evidence of efficacy [149]. Moreover, a double-blind, randomized phase IIb" exact="Brazilian" post="study by Borba et al. evaluated the efficacy and"/>
  <result pre="anti-inflammatory medication that is indicated for the treatment of gout," exact="familial" post="Mediterranean fever, and pericarditis (off-label) [151]. Colchicine exhibits anti-inflammatory"/>
  <result pre="medication that is indicated for the treatment of gout, familial" exact="Mediterranean fever," post="and pericarditis (off-label) [151]. Colchicine exhibits anti-inflammatory properties by"/>
  <result pre="indicated for the treatment of gout, familial Mediterranean fever, and" exact="pericarditis" post="(off-label) [151]. Colchicine exhibits anti-inflammatory properties by inhibiting the"/>
  <result pre="colchicine may decrease the release of surfactants by affecting alveolar" exact="type II" post="pneumocytes. At toxic doses, colchicine may further inhibit surfactantÂ"/>
  <result pre="inhibit surfactantÂ secretion, worsen ARDS, and cause multiorgan failure and" exact="disseminated intravascular coagulation." post="COLCORONA is a randomized, double-blind, placebo-controlled trial that is"/>
  <result pre="is currently evaluating the efficacy and safety of colchicine in" exact="adult" post="COVID-19 patients who have at least one high-risk criterion"/>
  <result pre="colchicine treatment on rates of hospitalization or death from the" exact="syndrome" post="30Â days after enrollment. Patients will receive colchicine 0.5Â"/>
  <result pre="currently not FDA-approved Anti-cytokine, IL-1 receptor antagonist Injection site reactions," exact="upper" post="respiratory tract infections, headache, nausea, diarrhea, sinusitis, flu-like symptoms,"/>
  <result pre="not FDA-approved Anti-cytokine, IL-1 receptor antagonist Injection site reactions, upper" exact="respiratory" post="tract infections, headache, nausea, diarrhea, sinusitis, flu-like symptoms, abdominal"/>
  <result pre="infections, headache, nausea, diarrhea, sinusitis, flu-like symptoms, abdominal pain Known" exact="hypersensitivity" post="to Escherichia coli-derived proteins, anakinra, or any component of"/>
  <result pre="Avoid use with anti-TNF agents due to higher rates of" exact="infections" post="and neutropenia Use caution in the elderly due to"/>
  <result pre="with anti-TNF agents due to higher rates of infections and" exact="neutropenia" post="Use caution in the elderly due to higher rates"/>
  <result pre="Use caution in the elderly due to higher rates of" exact="infections" post="in the elderly population In patients with CrClâ€‰ Tocilizumab"/>
  <result pre="the SC form Anti-cytokine, IL-6 receptor antagonist Injection site reactions," exact="upper" post="respiratory tract infections (including tuberculosis), nasopharyngitis, headache, hypertension, increased"/>
  <result pre="SC form Anti-cytokine, IL-6 receptor antagonist Injection site reactions, upper" exact="respiratory" post="tract infections (including tuberculosis), nasopharyngitis, headache, hypertension, increased ALT,"/>
  <result pre="Anti-cytokine, IL-6 receptor antagonist Injection site reactions, upper respiratory tract" exact="infections" post="(including tuberculosis), nasopharyngitis, headache, hypertension, increased ALT, hematological effects"/>
  <result pre="(including tuberculosis), nasopharyngitis, headache, hypertension, increased ALT, hematological effects Known" exact="hypersensitivity" post="to tocilizumab May decrease serum concentration of CYP3A4 substrates"/>
  <result pre="Anti-cytokine, IL-6 receptor antagonist Neutropenia, increased ALT, injection site erythema," exact="upper" post="respiratory infections, urinary tract infections Known hypersensitivity to sarilumab"/>
  <result pre="IL-6 receptor antagonist Neutropenia, increased ALT, injection site erythema, upper" exact="respiratory" post="infections, urinary tract infections Known hypersensitivity to sarilumab or"/>
  <result pre="antagonist Neutropenia, increased ALT, injection site erythema, upper respiratory infections," exact="urinary tract infections" post="Known hypersensitivity to sarilumab or any of its inactive"/>
  <result pre="increased ALT, injection site erythema, upper respiratory infections, urinary tract" exact="infections" post="Known hypersensitivity to sarilumab or any of its inactive"/>
  <result pre="injection site erythema, upper respiratory infections, urinary tract infections Known" exact="hypersensitivity" post="to sarilumab or any of its inactive ingredients May"/>
  <result pre="mg od for 14Â days PO Anti-cytokine, JAK1/JAK2Â inhibitor Upper" exact="respiratory" post="tract infections, nausea, herpes simplex, herpes zoster None SubstrateÂ"/>
  <result pre="days PO Anti-cytokine, JAK1/JAK2Â inhibitor Upper respiratory tract infections, nausea," exact="herpes" post="simplex, herpes zoster None SubstrateÂ of BCRP/ABCG2, CYP3A4, OAT1/3,"/>
  <result pre="Anti-cytokine, JAK1/JAK2Â inhibitor Upper respiratory tract infections, nausea, herpes simplex," exact="herpes zoster" post="None SubstrateÂ of BCRP/ABCG2, CYP3A4, OAT1/3, P-gp/ABCB1 Avoid use"/>
  <result pre="JAK1/JAK2Â inhibitor Upper respiratory tract infections, nausea, herpes simplex, herpes" exact="zoster" post="None SubstrateÂ of BCRP/ABCG2, CYP3A4, OAT1/3, P-gp/ABCB1 Avoid use"/>
  <result pre="Adalimumab Not described Injection, specifics not described Anti-cytokine, anti-TNFÎ± Upper" exact="respiratory" post="tract infections, sinusitis, increased macrophage-dependent infection, tuberculosis, opportunistic infections,"/>
  <result pre="anti-TNFÎ± Upper respiratory tract infections, sinusitis, increased macrophage-dependent infection, tuberculosis," exact="opportunistic infections," post="injection site reactions, increased creatine phosphokinase, headache, rash None"/>
  <result pre="increased macrophage-dependent infection, tuberculosis, opportunistic infections, injection site reactions, increased" exact="creatine phosphokinase," post="headache, rash None Avoid use with anakinra due to"/>
  <result pre="None Avoid use with anakinra due to higher rates of" exact="infections" post="and neutropenia Use with caution in patients with heart"/>
  <result pre="use with anakinra due to higher rates of infections and" exact="neutropenia" post="Use with caution in patients with heart failure or"/>
  <result pre="of infections and neutropenia Use with caution in patients with" exact="heart" post="failure or decreased left ventricular function; may cause myocardial"/>
  <result pre="underlying myocardial dysfunction Use caution in elderly patients; may increase" exact="infection" post="risk Sargramostim 125Â Î¼g bid for 5Â days Nebulized"/>
  <result pre="5Â days Nebulized inhalation Recombinant humanized GM-CSF Fever, hypertension, edema," exact="pericardial effusion," post="chest pain, peripheral edema, tachycardia, central nervous system effects,"/>
  <result pre="Nebulized inhalation Recombinant humanized GM-CSF Fever, hypertension, edema, pericardial effusion," exact="chest" post="pain, peripheral edema, tachycardia, central nervous system effects, dermatologic"/>
  <result pre="Recombinant humanized GM-CSF Fever, hypertension, edema, pericardial effusion, chest pain," exact="peripheral" post="edema, tachycardia, central nervous system effects, dermatologic effects, endocrine"/>
  <result pre="Fever, hypertension, edema, pericardial effusion, chest pain, peripheral edema, tachycardia," exact="central nervous system" post="effects, dermatologic effects, endocrine and metabolic changes, GI effects,"/>
  <result pre="system effects, dermatologic effects, endocrine and metabolic changes, GI effects," exact="urinary tract infections," post="hyperbilirubinemia, neuromuscular and skeletal effects, retinal hemorrhage, increased serum"/>
  <result pre="skeletal effects, retinal hemorrhage, increased serum creatinine, pharyngitis, epistaxis, dyspneaa" exact="Hypersensitivity" post="to human GM-CSF, yeast-derived products, or any component of"/>
  <result pre="myeloproliferation (e.g. corticosteroids) Use with caution in patients with pre-existing" exact="cardiac disease;" post="may cause supraventricular arrhythmia Safety during pregnancy and lactation"/>
  <result pre="caution in patients with pre-existing cardiac disease; may cause supraventricular" exact="arrhythmia" post="Safety during pregnancy and lactation is unknown Gimsilumab (investigational"/>
  <result pre="IV Neutralizing antibodies provide short-term passive immunity Inadvertent transmission of" exact="infectious" post="agents, allergic reactions, thrombotic complications, transfusion-associated circulatory overload, transfusion-related"/>
  <result pre="infectious agents, allergic reactions, thrombotic complications, transfusion-associated circulatory overload, transfusion-related" exact="acute" post="lung injury Allergy to human plasma, sodium citrate, methylene"/>
  <result pre="IgA-deficient patients with antibodies to IgA and a history of" exact="hypersensitivity" post="None Not recommended in patients with heart failure, chronic"/>
  <result pre="a history of hypersensitivity None Not recommended in patients with" exact="heart" post="failure, chronic kidney failure in the dialysis phase, and"/>
  <result pre="of hypersensitivity None Not recommended in patients with heart failure," exact="chronic" post="kidney failure in the dialysis phase, and organ transplant"/>
  <result pre="hypersensitivity None Not recommended in patients with heart failure, chronic" exact="kidney failure" post="in the dialysis phase, and organ transplant Non-specific immunomodulators"/>
  <result pre="dyspnea, cough, sore throat, malaise, myalgia, arthralgia, abdominal pain, leukopenia," exact="aseptic meningitis," post="infections, acute renal failure, stroke, myocardial infarction, deep vein"/>
  <result pre="throat, malaise, myalgia, arthralgia, abdominal pain, leukopenia, aseptic meningitis, infections," exact="acute" post="renal failure, stroke, myocardial infarction, deep vein thrombosis, pulmonary"/>
  <result pre="malaise, myalgia, arthralgia, abdominal pain, leukopenia, aseptic meningitis, infections, acute" exact="renal failure," post="stroke, myocardial infarction, deep vein thrombosis, pulmonary embolism, anaphylactic"/>
  <result pre="abdominal pain, leukopenia, aseptic meningitis, infections, acute renal failure, stroke," exact="myocardial infarction," post="deep vein thrombosis, pulmonary embolism, anaphylactic shock History of"/>
  <result pre="leukopenia, aseptic meningitis, infections, acute renal failure, stroke, myocardial infarction," exact="deep vein thrombosis," post="pulmonary embolism, anaphylactic shock History of anaphylactic or severe"/>
  <result pre="infections, acute renal failure, stroke, myocardial infarction, deep vein thrombosis," exact="pulmonary embolism," post="anaphylactic shock History of anaphylactic or severe systemic reaction"/>
  <result pre="thrombosis, pulmonary embolism, anaphylactic shock History of anaphylactic or severe" exact="systemic" post="reaction to human immune globulin Patients with hyperprolinemia; IVIG"/>
  <result pre="IgA-deficient patients with antibodies to IgA and a history of" exact="hypersensitivity" post="Live virus vaccines (measles, mumps, rubella, varicella) Use with"/>
  <result pre="caution in elderly patients; may be at higher risk for" exact="renal failure" post="and thromboembolic events. Administer the minimum dose at the"/>
  <result pre="and antifibrotic effects to prevent extended cytokine response Sodium and" exact="water retention" post="(less than methylprednisolone), hypertension, hyperglycemia, osteoporosis, cardiac hypertrophy, edema,"/>
  <result pre="edema, hypokalemia, bruising, diaphoresis, urticaria, allergic rash, euphoria, psychosis, infections," exact="myasthenia gravis" post="Hypersensitivity to corticosteroids or any component of the formulation,"/>
  <result pre="bruising, diaphoresis, urticaria, allergic rash, euphoria, psychosis, infections, myasthenia gravis" exact="Hypersensitivity" post="to corticosteroids or any component of the formulation, systemic"/>
  <result pre="gravis Hypersensitivity to corticosteroids or any component of the formulation," exact="systemic" post="fungal infection SubstrateÂ of CYP3A4 and P-gp/ABCB1. Live or"/>
  <result pre="Hypersensitivity to corticosteroids or any component of the formulation, systemic" exact="fungal infection" post="SubstrateÂ of CYP3A4 and P-gp/ABCB1. Live or attenuated virus"/>
  <result pre="to corticosteroids or any component of the formulation, systemic fungal" exact="infection" post="SubstrateÂ of CYP3A4 and P-gp/ABCB1. Live or attenuated virus"/>
  <result pre="edema, hypokalemia, bruising, diaphoresis, urticaria, allergic rash, euphoria, psychosis, infections," exact="myasthenia gravis" post="Hypersensitivity to corticosteroids or any component of the formulation,"/>
  <result pre="bruising, diaphoresis, urticaria, allergic rash, euphoria, psychosis, infections, myasthenia gravis" exact="Hypersensitivity" post="to corticosteroids or any component of the formulation, systemic"/>
  <result pre="gravis Hypersensitivity to corticosteroids or any component of the formulation," exact="systemic" post="fungal infection CYP3A4 substrate Live or attenuated virus vaccines"/>
  <result pre="Hypersensitivity to corticosteroids or any component of the formulation, systemic" exact="fungal infection" post="CYP3A4 substrate Live or attenuated virus vaccines (if using"/>
  <result pre="to corticosteroids or any component of the formulation, systemic fungal" exact="infection" post="CYP3A4 substrate Live or attenuated virus vaccines (if using"/>
  <result pre="be continued in COVID-19 patients with an underlying condition (e.g." exact="primary" post="or secondary adrenal insufficiency, rheumatologic diseases) Inhaled corticosteroids should"/>
  <result pre="in COVID-19 patients with an underlying condition (e.g. primary or" exact="secondary" post="adrenal insufficiency, rheumatologic diseases) Inhaled corticosteroids should be continued"/>
  <result pre="COVID-19 patients with an underlying condition (e.g. primary or secondary" exact="adrenal insufficiency," post="rheumatologic diseases) Inhaled corticosteroids should be continued in COVID-19"/>
  <result pre="diseases) Inhaled corticosteroids should be continued in COVID-19 patients with" exact="asthma" post="and COPD Corticosteroid treatment in pregnant women should be"/>
  <result pre="headache, hypertonia, insomnia, asthenia, myalgia, flu-like symptoms, fever History of" exact="hypersensitivity" post="to natural or recombinant interferonÎ², albumin (human), or any"/>
  <result pre="studies have been conducted Use with caution in patients with" exact="bone marrow suppression," post="cardiovascular disease, hepatic impairment Interferon-Î±-2b 5 million units bid"/>
  <result pre="conducted Use with caution in patients with bone marrow suppression," exact="cardiovascular disease," post="hepatic impairment Interferon-Î±-2b 5 million units bid Nebulized Antiviral"/>
  <result pre="ataxia, chills, headache, hypertonia, insomnia, asthenia, myalgia, flu-like symptoms, fever," exact="hemolytic anemia" post="Hypersensitivity to interferon-Î± or any component of the formulation,"/>
  <result pre="chills, headache, hypertonia, insomnia, asthenia, myalgia, flu-like symptoms, fever, hemolytic" exact="anemia" post="Hypersensitivity to interferon-Î± or any component of the formulation,"/>
  <result pre="headache, hypertonia, insomnia, asthenia, myalgia, flu-like symptoms, fever, hemolytic anemia" exact="Hypersensitivity" post="to interferon-Î± or any component of the formulation, decompensated"/>
  <result pre="Hypersensitivity to interferon-Î± or any component of the formulation, decompensated" exact="liver disease," post="autoimmune hepatitis Not fully evaluated Use with caution in"/>
  <result pre="interferon-Î± or any component of the formulation, decompensated liver disease," exact="autoimmune hepatitis" post="Not fully evaluated Use with caution in patients with"/>
  <result pre="or any component of the formulation, decompensated liver disease, autoimmune" exact="hepatitis" post="Not fully evaluated Use with caution in patients with"/>
  <result pre="caution in patients with a history of neuropsychiatric, autoimmune, ischemic," exact="infectious" post="disorders, and patients with pre-existing heart disease and organ"/>
  <result pre="of neuropsychiatric, autoimmune, ischemic, infectious disorders, and patients with pre-existing" exact="heart" post="disease and organ transplant Miscellaneous Statins Simvastatin 40Â mg"/>
  <result pre="neuropsychiatric, autoimmune, ischemic, infectious disorders, and patients with pre-existing heart" exact="disease" post="and organ transplant Miscellaneous Statins Simvastatin 40Â mg od"/>
  <result pre="immunomodulatory effects Hepatotoxicity, myopathies, GI effects, rhabdomyolysis, increased risk of" exact="diabetes" post="Hypersensitivity to statin or any component of the formulation,"/>
  <result pre="effects Hepatotoxicity, myopathies, GI effects, rhabdomyolysis, increased risk of diabetes" exact="Hypersensitivity" post="to statin or any component of the formulation, active"/>
  <result pre="Hypersensitivity to statin or any component of the formulation, active" exact="liver disease;" post="unexplained persistent elevations of serum transaminases; pregnancy, breastfeeding Inhibitors/substrates"/>
  <result pre="caution in elderly patients; may be at higher riskÂ forÂ" exact="myopathy" post="Statins may need to be withheld for a short"/>
  <result pre="forÂ myopathy Statins may need to be withheld for a" exact="short" post="time period in COVID-19 patients with severe rhabdomyolysis ACEi/ARB"/>
  <result pre="for a short time period in COVID-19 patients with severe" exact="rhabdomyolysis" post="ACEi/ARB Various dosing regimens: telmisartan 80Â mg bid, telmisartan"/>
  <result pre="and immunomodulatory effects Cough (more common with ACEi), hyperkalemia, edema," exact="angioedema" post="(more common with ACEi), photosensitivity, renal failure, dysgeusia, headache"/>
  <result pre="with ACEi), hyperkalemia, edema, angioedema (more common with ACEi), photosensitivity," exact="renal failure," post="dysgeusia, headache Previous angioneurotic edema (ACEi), pregnancy, hyperkalemia, bilateral"/>
  <result pre="(more common with ACEi), photosensitivity, renal failure, dysgeusia, headache Previous" exact="angioneurotic edema" post="(ACEi), pregnancy, hyperkalemia, bilateral renal stenosis, pregnancy Risk of"/>
  <result pre="renal failure, dysgeusia, headache Previous angioneurotic edema (ACEi), pregnancy, hyperkalemia," exact="bilateral" post="renal stenosis, pregnancy Risk of hyperkalemia may be increased"/>
  <result pre="QTc prolongation and ventricular arrhythmias, diarrhea, nausea, abdominal pain, vomiting" exact="Hypersensitivity" post="to azithromycin or other macrolides, history of cholestatic jaundice/hepatic"/>
  <result pre="G-6-PD deficiency, hypoglycemia, retinopathy, nervous system disorders, psychiatric disorders Known" exact="hypersensitivity" post="to hydroxychloroquine, 4-aminoquinoline derivatives, or any component of the"/>
  <result pre="abdominal pain), neuromuscular toxicity, hematological effects, elevated AST and ALT" exact="Renal" post="or hepatic impairment in conjunction with drugs that inhibit"/>
  <result pre="angiotensin II receptor blockers, AST aminotransferase, bid twice daily, COPD" exact="chronic" post="obstructive pulmonary disease, COVID-19 coronavirus disease 2019, CrCl creatinine"/>
  <result pre="receptor blockers, AST aminotransferase, bid twice daily, COPD chronic obstructive" exact="pulmonary" post="disease, COVID-19 coronavirus disease 2019, CrCl creatinine clearance, CYP"/>
  <result pre="bid twice daily, COPD chronic obstructive pulmonary disease, COVID-19 coronavirus" exact="disease" post="2019, CrCl creatinine clearance, CYP cytochrome P450, ESRD end-stage"/>
  <result pre="coronavirus disease 2019, CrCl creatinine clearance, CYP cytochrome P450, ESRD" exact="end-stage renal disease," post="G-6-PD glucose-6-phosphate dehydrogenase, GI gastrointestinal, GM-CSF granulocyteâ€&quot;macrophage colony-stimulating factor,"/>
  <result pre="disease 2019, CrCl creatinine clearance, CYP cytochrome P450, ESRD end-stage" exact="renal disease," post="G-6-PD glucose-6-phosphate dehydrogenase, GI gastrointestinal, GM-CSF granulocyteâ€&quot;macrophage colony-stimulating factor,"/>
  <result pre="P-glycoprotein, PO oral, SC subcutaneous, tid three times daily, TNF" exact="tumor" post="necrosis factor aReported with the IV and SC forms"/>
  <result pre="the drug Conclusion COVID-19 is increasingly being recognized as a" exact="syndrome" post="of viral replication and host inflammatory response. Effective pharmaco-immunomodulating"/>
  <result pre="Conclusion COVID-19 is increasingly being recognized as a syndrome of" exact="viral" post="replication and host inflammatory response. Effective pharmaco-immunomodulating strategies may"/>
  <result pre="and host inflammatory response. Effective pharmaco-immunomodulating strategies may help alleviate" exact="syndrome" post="progression, especially in the more advanced stages of COVID-19."/>
  <result pre="more advanced stages of COVID-19. Considering the immune dysfunction and" exact="lymphopenia" post="in COVID-19, several immunomodulators are under development or are"/>
  <result pre="pathogen-specific adaptive immune responses have been demonstrated with Hemophilus influenzae" exact="respiratory" post="infection [160]. Furthermore, ILC2s, despite their scarcity, are the"/>
  <result pre="adaptive immune responses have been demonstrated with Hemophilus influenzae respiratory" exact="infection" post="[160]. Furthermore, ILC2s, despite their scarcity, are the dominant"/>
  <result pre="profile and has been used orally as a treatment for" exact="allergic rhinitis" post="in Japan for the past 20Â years. Hence, clinical"/>
  <result pre="and has been used orally as a treatment for allergic" exact="rhinitis" post="in Japan for the past 20Â years. Hence, clinical"/>
  <result pre="Abbott, Abbvie, ACI Clinical (Cara Therapeutics), Akebia, Alexion, Amgen, Ardelyx," exact="American" post="Society of Nephrology (ASN), Astra-Zeneca, Aveo, BBraun, Chugai, Cytokinetics,"/>
  <result pre="Fresenius, Genentech, Haymarket Media, Hofstra Medical School, International Federation of" exact="Kidney" post="Foundations (IFKF), International Society of Hemodialysis (ISH), International Society"/>
  <result pre="Foundations (IFKF), International Society of Hemodialysis (ISH), International Society of" exact="Renal" post="Nutrition and Metabolism (ISRNM), Japanese Society of Dialysis Therapy"/>
  <result pre="Society of Hemodialysis (ISH), International Society of Renal Nutrition and" exact="Metabolism" post="(ISRNM), Japanese Society of Dialysis Therapy (JSDT), Hospira, Kabi,"/>
  <result pre="Keryx, Kissei, Novartis, OPKO, National Institutes of Health (NIH), National" exact="Kidney" post="Foundation (NKF), Pfizer, Regulus, Relypsa, Resverlogix, Dr Schaer, Sandoz,"/>
  <result pre="illness in native and immunosuppressed states: a clinical-therapeutic staging proposalJ" exact="Heart" post="Lung Transplant202039540540710.1016/j.healun.2020.03.01232362390 2.RodrÃ­guezYNovelliLRojasMet al.Autoinflammatory and autoimmune conditions at the"/>
  <result pre="a clinical-therapeutic staging proposalJ Heart Lung Transplant202039540540710.1016/j.healun.2020.03.01232362390 2.RodrÃ­guezYNovelliLRojasMet al.Autoinflammatory and" exact="autoimmune" post="conditions at the crossroad of COVID-19J Autoimmun202010.1016/j.jaut.2020.10250632563547 3.WuFZhaoSYuBet al.A"/>
  <result pre="of COVID-19J Autoimmun202010.1016/j.jaut.2020.10250632563547 3.WuFZhaoSYuBet al.A new coronavirus associated with human" exact="respiratory" post="disease in China [published correction appears in Nature. 2020;580(7803):E7]Nature2020579779826526910.1038/s41586-020-2008-332015508"/>
  <result pre="COVID-19J Autoimmun202010.1016/j.jaut.2020.10250632563547 3.WuFZhaoSYuBet al.A new coronavirus associated with human respiratory" exact="disease" post="in China [published correction appears in Nature. 2020;580(7803):E7]Nature2020579779826526910.1038/s41586-020-2008-332015508 4.HuangCWangYLiXRenLZhaoJHuYet"/>
  <result pre="infected with 2019 novel coronavirus in WuhanChina Lancet202039549750610.1016/S0140-6736(20)30183-531986264 5.ChanJFYuanSKokKHToKKChuHYangJet al.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
  <result pre="novel coronavirus in WuhanChina Lancet202039549750610.1016/S0140-6736(20)30183-531986264 5.ChanJFYuanSKokKHToKKChuHYangJet al.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
  <result pre="study of a family clusterLancet202039551452310.1016/S0140-6736(20)30154-931986261 6.WuCChenXCaiYet al.Risk factors associated with" exact="acute" post="respiratory distress syndrome and death in patients with coronavirus"/>
  <result pre="of a family clusterLancet202039551452310.1016/S0140-6736(20)30154-931986261 6.WuCChenXCaiYet al.Risk factors associated with acute" exact="respiratory" post="distress syndrome and death in patients with coronavirus disease"/>
  <result pre="family clusterLancet202039551452310.1016/S0140-6736(20)30154-931986261 6.WuCChenXCaiYet al.Risk factors associated with acute respiratory distress" exact="syndrome" post="and death in patients with coronavirus disease 2019 pneumonia"/>
  <result pre="acute respiratory distress syndrome and death in patients with coronavirus" exact="disease" post="2019 pneumonia in WuhanChina JAMA Intern Med2020180711110.1001/jamainternmed.2020.0994 7.MahallawiWHKhabourOFZhangQMakhdoumHMSulimanBAMERS-CoV infection"/>
  <result pre="distress syndrome and death in patients with coronavirus disease 2019" exact="pneumonia" post="in WuhanChina JAMA Intern Med2020180711110.1001/jamainternmed.2020.0994 7.MahallawiWHKhabourOFZhangQMakhdoumHMSulimanBAMERS-CoV infection in humans"/>
  <result pre="coronavirus disease 2019 pneumonia in WuhanChina JAMA Intern Med2020180711110.1001/jamainternmed.2020.0994 7.MahallawiWHKhabourOFZhangQMakhdoumHMSulimanBAMERS-CoV" exact="infection" post="in humans is associated with a pro-inflammatory Th1 and"/>
  <result pre="cytokine profileCytokine20181048â€&quot;1324 8.WongCKLamCWWuAKIpWKLeeNLChanIHet al.Plasma inflammatory cytokines and chemokines in severe" exact="acute" post="respiratory syndromeClin Exp Immunol20041369510310.1111/j.1365-2249.2004.02415.x15030519 9.ShiYWangYShaoCHuangJGanJHuangXet al.COVID-19 infection: the perspectives"/>
  <result pre="profileCytokine20181048â€&quot;1324 8.WongCKLamCWWuAKIpWKLeeNLChanIHet al.Plasma inflammatory cytokines and chemokines in severe acute" exact="respiratory" post="syndromeClin Exp Immunol20041369510310.1111/j.1365-2249.2004.02415.x15030519 9.ShiYWangYShaoCHuangJGanJHuangXet al.COVID-19 infection: the perspectives on"/>
  <result pre="al.COVID-19: consider cytokine storm syndromes and immunosuppressionLancet2020395102291033103410.1016/S0140-6736(20)30628-032192578 12.McGonagleDO'DonnellJSSharifKEmeryPBridgewoodCImmune mechanisms of" exact="pulmonary" post="intravascular coagulopathy in COVID-19 pneumoniaLancet Rheumatol20202e437e44510.1016/S2665-9913(20)30121-1 13.WebsterNRGalleyHFImmunomodulation in the"/>
  <result pre="cytokine storm syndromes and immunosuppressionLancet2020395102291033103410.1016/S0140-6736(20)30628-032192578 12.McGonagleDO'DonnellJSSharifKEmeryPBridgewoodCImmune mechanisms of pulmonary intravascular" exact="coagulopathy" post="in COVID-19 pneumoniaLancet Rheumatol20202e437e44510.1016/S2665-9913(20)30121-1 13.WebsterNRGalleyHFImmunomodulation in the critically illBr"/>
  <result pre="New Directions in the Study of Antimicrobial Therapeutics: Immunomodulation.Â Treating" exact="Infectious" post="Diseases in a Microbial World: Report of Two Workshops"/>
  <result pre="Directions in the Study of Antimicrobial Therapeutics: Immunomodulation.Â Treating Infectious" exact="Diseases" post="in a Microbial World: Report of Two Workshops on"/>
  <result pre="Orphan Biovitrum AB. KineretÂ® (anakinra) injection, solution prescribing information. Stockholm:" exact="Swedish" post="Orphan Biovitrum AB; 2018. 17.MonteagudoLABoothbyAGertnerEContinuous intravenous anakinra infusion to"/>
  <result pre="in macrophage activation syndromeACR Open Rheumatol20202527628210.1002/acr2.1113532267081 18.SchulertGSGromAAPathogenesis of macrophage activation" exact="syndrome" post="and potential for cytokine-directed therapiesAnnu Rev Med20156614515910.1146/annurev-med-061813-01280625386930 19.ShakooryBCarcilloJAChathamWWet al.Interleukin-1"/>
  <result pre="22.DimopoulosGde MastQMarkouNet al.Favorable anakinra responses in severe Covid-19 patients with" exact="secondary" post="hemophagocytic lymphohistiocytosisCell Host Microbe2020281117123.e110.1016/j.chom.2020.05.00732411313 23.CaoXCOVID-19: immunopathology and its implications"/>
  <result pre="implications for therapyNat Rev Immunol202020526927010.1038/s41577-020-0308-332273594 24.KalyLRosnerITocilizumabâ€&quot;a novel therapy for non-organ-specific" exact="autoimmune" post="diseasesBest Pract Res Clin Rheumatol201226115716510.1016/j.berh.2012.01.00122424201 25.XuXHanMLiTet al.Effective treatment of"/>
  <result pre="and safety of tocilizumab in the treatment of new coronavirus" exact="pneumonia" post="(COVID-19). https://www.chictr.org.cn/showprojen.aspx?proj=49409. Accessed 15 June 2020. 30.Kevzara [package insert]."/>
  <result pre="J Antimicrob Agents202010.1016/j.ijantimicag.2020.10602332450201 36.RichardsonPGriffinITuckerCet al.Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory diseaseLancet202039510223e30e3110.1016/S0140-6736(20)30304-432032529 37.Olumiant [package insert]. Indianapolis, IN: Lilly USA,"/>
  <result pre="Antimicrob Agents202010.1016/j.ijantimicag.2020.10602332450201 36.RichardsonPGriffinITuckerCet al.Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="diseaseLancet202039510223e30e3110.1016/S0140-6736(20)30304-432032529 37.Olumiant [package insert]. Indianapolis, IN: Lilly USA, LLC;"/>
  <result pre="https://investor.lilly.com/news-releases/news-release-details/lilly-begins-clinicaltesting-therapies-covid-19. Accessed 10 Apr 2020. 42.National Institutes of Health. Coronavirus" exact="disease" post="2019 (COVID-19) treatment guidelines. https://www.covid19treatmentguidelines.nih.gov/). Accessed 11 May 2020."/>
  <result pre="immunomodulatory therapy: an overviewR I Med J (2013)201699121922 45.WangLHeWYuXet al.Coronavirus" exact="disease" post="2019 in elderly patients: characteristics and prognostic factors based"/>
  <result pre="and prognostic factors based on 4-week follow-upJ Infect202010.1016/j.jinf.2020.03.01932652165 46.HussellTPennycookAOpenshawPJInhibition of" exact="tumor" post="necrosis factor reduces the severity of virus-specific lung immunopathologyEur"/>
  <result pre="protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates" exact="viral" post="entryProc Natl Acad Sci USA2008105227809781410.1073/pnas.071124110518490652 48.GerrietsVBansalPKhaddourKTumor necrosis factor (TNF)"/>
  <result pre="are urgently neededLancet202010.1016/S0140-6736(20)30858-832278362 50.MahaseECovid-19: what treatments are being investigated?BMJ2020368m125210.1136/bmj.m125232217607 51.RÃ¶slerBHeroldSLung" exact="epithelial" post="GM-CSF improves host defense function and epithelial repair in"/>
  <result pre="being investigated?BMJ2020368m125210.1136/bmj.m125232217607 51.RÃ¶slerBHeroldSLung epithelial GM-CSF improves host defense function and" exact="epithelial" post="repair in influenza virus pneumonia-a new therapeutic strategy?Mol Cell"/>
  <result pre="Pediatr2016312910.1186/s40348-016-0055-527480877 52.HeroldSHoegnerKVadÃ¡szIet al.Inhaled granulocyte/macrophage colony-stimulating factor as treatment of pneumonia-associated" exact="acute" post="respiratory distress syndromeAm J Respir Crit Care Med2014189560961110.1164/rccm.201311-2041LE24579839 53.Matute-BelloGLilesWCRadellaF2ndSteinbergKPRuzinskiJTHudsonLDMartinTRModulation"/>
  <result pre="52.HeroldSHoegnerKVadÃ¡szIet al.Inhaled granulocyte/macrophage colony-stimulating factor as treatment of pneumonia-associated acute" exact="respiratory" post="distress syndromeAm J Respir Crit Care Med2014189560961110.1164/rccm.201311-2041LE24579839 53.Matute-BelloGLilesWCRadellaF2ndSteinbergKPRuzinskiJTHudsonLDMartinTRModulation of"/>
  <result pre="colony-stimulating factor and granulocyte/macrophage colony-stimulating factor during the course of" exact="acute" post="respiratory distress syndromeCrit Care Med20002811710.1097/00003246-200001000-0000110667491 54.OvergaardCESchlingmannBDorsainvil WhiteSCWardCFanXSwarnakarSBrownLAGuidotDMKovalMThe relative balance"/>
  <result pre="factor and granulocyte/macrophage colony-stimulating factor during the course of acute" exact="respiratory" post="distress syndromeCrit Care Med20002811710.1097/00003246-200001000-0000110667491 54.OvergaardCESchlingmannBDorsainvil WhiteSCWardCFanXSwarnakarSBrownLAGuidotDMKovalMThe relative balance of"/>
  <result pre="54.OvergaardCESchlingmannBDorsainvil WhiteSCWardCFanXSwarnakarSBrownLAGuidotDMKovalMThe relative balance of GM-CSF and TGF-Î²1 regulates lung" exact="epithelial" post="barrier functionAm J Physiol Lung Cell Mol Physiol201530812L1212L122310.1152/ajplung.00042.201425888574 55.BhattacharyaPBudnickISinghMet"/>
  <result pre="pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe" exact="pulmonary" post="syndrome patients of a new coronavirus [pre-print]BioRxiv202010.1101/2020.02.12.94557632676596 57.PaineRStandifordTJDechertREet al.A"/>
  <result pre="GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary" exact="syndrome" post="patients of a new coronavirus [pre-print]BioRxiv202010.1101/2020.02.12.94557632676596 57.PaineRStandifordTJDechertREet al.A randomized"/>
  <result pre="of recombinant human granulocyte-macrophage colony stimulating factor for patients with" exact="acute" post="lung injuryCrit Care Med2012401909710.1097/CCM.0b013e31822d7bf021926600 58.PresneillJJHarrisTStewartAGCadeJFWilsonJWA randomized phase II trial"/>
  <result pre="trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with" exact="respiratory" post="dysfunctionAm J Respir Crit Care Med200216613814310.1164/rccm.200900512119223 59.ZhouYFuBZhengXet al.Pathogenic T"/>
  <result pre="anti-inflammatory drugs in the treatment of people with severe coronavirus" exact="disease" post="2019 (COVID-19): the perspectives of clinical immunologists from ChinaClin"/>
  <result pre="effects of convalescent plasma therapy for patients with Middle East" exact="respiratory" post="syndrome coronavirus infection: a study protocolSpringerplus2015470910.1186/s40064-015-1490-926618098 71.HungIFToKKLeeCKet al.Convalescent plasma"/>
  <result pre="of convalescent plasma therapy for patients with Middle East respiratory" exact="syndrome" post="coronavirus infection: a study protocolSpringerplus2015470910.1186/s40064-015-1490-926618098 71.HungIFToKKLeeCKet al.Convalescent plasma treatment"/>
  <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: a systematic review and"/>
  <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: a systematic review and exploratory"/>
  <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: a systematic review and exploratory meta-analysisJ"/>
  <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: a systematic review and exploratory meta-analysisJ Infect Dis20152111809010.1093/infdis/jiu39625030060"/>
  <result pre="IL: CSL Behring LLC; 2007.https://www.fda.gov/media/83304/download. Accessed 7 May 2020. 78.StockmanLJBellamyRGarnerPSARS:" exact="systemic" post="review of treatment effectsPLoS Med20063e34310.1371/journal.pmed.003034316968120 79.UmapathiTKorACVenketasubramanianNet al.Large artery ischaemic"/>
  <result pre="systemic review of treatment effectsPLoS Med20063e34310.1371/journal.pmed.003034316968120 79.UmapathiTKorACVenketasubramanianNet al.Large artery ischaemic" exact="stroke" post="in severe acute respiratory syndrome (SARS)J Neurol20042511227123110.1007/s00415-004-0519-915503102 80.NgKHLWuAKLChengVCCet al.Pulmonary"/>
  <result pre="treatment effectsPLoS Med20063e34310.1371/journal.pmed.003034316968120 79.UmapathiTKorACVenketasubramanianNet al.Large artery ischaemic stroke in severe" exact="acute" post="respiratory syndrome (SARS)J Neurol20042511227123110.1007/s00415-004-0519-915503102 80.NgKHLWuAKLChengVCCet al.Pulmonary artery thrombosis in"/>
  <result pre="effectsPLoS Med20063e34310.1371/journal.pmed.003034316968120 79.UmapathiTKorACVenketasubramanianNet al.Large artery ischaemic stroke in severe acute" exact="respiratory" post="syndrome (SARS)J Neurol20042511227123110.1007/s00415-004-0519-915503102 80.NgKHLWuAKLChengVCCet al.Pulmonary artery thrombosis in a"/>
  <result pre="Med20063e34310.1371/journal.pmed.003034316968120 79.UmapathiTKorACVenketasubramanianNet al.Large artery ischaemic stroke in severe acute respiratory" exact="syndrome" post="(SARS)J Neurol20042511227123110.1007/s00415-004-0519-915503102 80.NgKHLWuAKLChengVCCet al.Pulmonary artery thrombosis in a patient"/>
  <result pre="in severe acute respiratory syndrome (SARS)J Neurol20042511227123110.1007/s00415-004-0519-915503102 80.NgKHLWuAKLChengVCCet al.Pulmonary artery" exact="thrombosis" post="in a patient with severe acute respiratory syndromePostgrad Med"/>
  <result pre="Neurol20042511227123110.1007/s00415-004-0519-915503102 80.NgKHLWuAKLChengVCCet al.Pulmonary artery thrombosis in a patient with severe" exact="acute" post="respiratory syndromePostgrad Med J200581e310.1136/pgmj.2004.03004915937197 81.NguyenAAHabiballahSBPlattCDGehaRSChouJSMcDonaldDRImmunoglobulins in the treatment of"/>
  <result pre="80.NgKHLWuAKLChengVCCet al.Pulmonary artery thrombosis in a patient with severe acute" exact="respiratory" post="syndromePostgrad Med J200581e310.1136/pgmj.2004.03004915937197 81.NguyenAAHabiballahSBPlattCDGehaRSChouJSMcDonaldDRImmunoglobulins in the treatment of COVID-19"/>
  <result pre="COVID-19 infection: proceed with caution!Clin Immunol202021610845910.1016/j.clim.2020.10845932418917 82.GaleottiCKaveriSVBayryJIVIG-mediated effector functions in" exact="autoimmune" post="and inflammatory diseasesInt Immunol2017291149149810.1093/intimm/dxx03928666326 83.CaoWLiuXBaiTet al.High-dose intravenous immunoglobulin as"/>
  <result pre="immunoglobulin as a therapeutic option for deteriorating patients with coronavirus" exact="disease" post="2019Open Forum Infect Dis202073ofaa10210.1093/ofid/ofaa10232258207 84.XieYCaoSDongHet al.Effect of regular intravenous"/>
  <result pre="al.Effect of regular intravenous immunoglobulin therapy on prognosis of severe" exact="pneumonia" post="in patients with COVID-19J Infect202010.1016/j.jinf.2020.03.04432579986 85.AlhazzaniWMÃ¸llerMHArabiYMet al.Surviving sepsis campaign:"/>
  <result pre="guidelines on the management of critically ill adults with coronavirus" exact="disease" post="2019 (COVID-19)Crit Care Med2020486e440e46910.1097/CCM.000000000000436332224769 86.RussellCDMillarJEBaillieJKClinical evidence does not support"/>
  <result pre="for 2019-nCoV pneumoniaLancet202039568368410.1016/S0140-6736(20)30361-532122468 92.VillarJConfalonieriMPastoresSMeduriGUmbertoMDRationale for prolonged corticosteroid treatment in the" exact="acute" post="respiratory distress syndrome caused by coronavirus disease 2019Crit Care"/>
  <result pre="2019-nCoV pneumoniaLancet202039568368410.1016/S0140-6736(20)30361-532122468 92.VillarJConfalonieriMPastoresSMeduriGUmbertoMDRationale for prolonged corticosteroid treatment in the acute" exact="respiratory" post="distress syndrome caused by coronavirus disease 2019Crit Care Explor202024e011110.1097/CCE.000000000000011132426753"/>
  <result pre="92.VillarJConfalonieriMPastoresSMeduriGUmbertoMDRationale for prolonged corticosteroid treatment in the acute respiratory distress" exact="syndrome" post="caused by coronavirus disease 2019Crit Care Explor202024e011110.1097/CCE.000000000000011132426753 93.RodrigoCLeonardi-BeeJNguyen-Van-TamJLimWSCorticosteroids as"/>
  <result pre="treatment in the acute respiratory distress syndrome caused by coronavirus" exact="disease" post="2019Crit Care Explor202024e011110.1097/CCE.000000000000011132426753 93.RodrigoCLeonardi-BeeJNguyen-Van-TamJLimWSCorticosteroids as adjunctive therapy in the"/>
  <result pre="94.ArabiYMMandourahYAl-HameedFSindiAAAlmekhlafiGAHusseinMAet al.Corticosteroid therapy for critically ill patients with Middle East" exact="respiratory" post="syndromeAm J Respir Crit Care Med2018197675776710.1164/rccm.201706-1172OC29161116 95.World Health Organization."/>
  <result pre="Crit Care Med2018197675776710.1164/rccm.201706-1172OC29161116 95.World Health Organization. Clinical management of severe" exact="acute" post="respiratory infection (SARI) when COVID-19 disease is suspected. Interim"/>
  <result pre="Care Med2018197675776710.1164/rccm.201706-1172OC29161116 95.World Health Organization. Clinical management of severe acute" exact="respiratory" post="infection (SARI) when COVID-19 disease is suspected. Interim guidance."/>
  <result pre="Med2018197675776710.1164/rccm.201706-1172OC29161116 95.World Health Organization. Clinical management of severe acute respiratory" exact="infection" post="(SARI) when COVID-19 disease is suspected. Interim guidance. 13"/>
  <result pre="Clinical management of severe acute respiratory infection (SARI) when COVID-19" exact="disease" post="is suspected. Interim guidance. 13 Mar 2020. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed"/>
  <result pre="13 Mar 2020. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed 19 Mar 2020. 96.Centers for" exact="Disease" post="Control. Healthcare professionals: frequently asked questions and answers. https://www.cdc.gov/coronavirus/2019-ncov/hcp/faq.html."/>
  <result pre="by up to one third in hospitalised patients with severe" exact="respiratory" post="complications of COVID-19. https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_v2final.pdf. Accessed 20 June 2020. 98.VillarJFerrandoCMartÃ­nezDet"/>
  <result pre="https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_v2final.pdf. Accessed 20 June 2020. 98.VillarJFerrandoCMartÃ­nezDet al.Dexamethasone treatment for the" exact="acute" post="respiratory distress syndrome: a multicentre, randomised controlled trialLancet Respir"/>
  <result pre="Accessed 20 June 2020. 98.VillarJFerrandoCMartÃ­nezDet al.Dexamethasone treatment for the acute" exact="respiratory" post="distress syndrome: a multicentre, randomised controlled trialLancet Respir Med20208326727610.1016/S2213-2600(19)30417-532043986"/>
  <result pre="Schindewolf C, Rajsbaum R, Menachery VD. SARS-CoV-2 is sensitive to" exact="type I" post="interferon pretreatment. Preprint. bioRxiv. 2020;2020.03.07.982264. Published 2020 Apr 9."/>
  <result pre="Opin Drug Discov201914439741210.1080/17460441.2019.158117130849247 103.LoutfyMRBlattLMSiminovitchKAet al.Interferon alfacon-1 plus corticosteroids in severe" exact="acute" post="respiratory syndrome: a preliminary studyJAMA2003290243222322810.1001/jama.290.24.322214693875 104.OmraniASSaadMMBaigKet al.Ribavirin and interferon"/>
  <result pre="Drug Discov201914439741210.1080/17460441.2019.158117130849247 103.LoutfyMRBlattLMSiminovitchKAet al.Interferon alfacon-1 plus corticosteroids in severe acute" exact="respiratory" post="syndrome: a preliminary studyJAMA2003290243222322810.1001/jama.290.24.322214693875 104.OmraniASSaadMMBaigKet al.Ribavirin and interferon alfa-2a"/>
  <result pre="studyJAMA2003290243222322810.1001/jama.290.24.322214693875 104.OmraniASSaadMMBaigKet al.Ribavirin and interferon alfa-2a for severe Middle East" exact="respiratory" post="syndrome coronavirus infection: a retrospective cohort study [published correction"/>
  <result pre="104.OmraniASSaadMMBaigKet al.Ribavirin and interferon alfa-2a for severe Middle East respiratory" exact="syndrome" post="coronavirus infection: a retrospective cohort study [published correction appears"/>
  <result pre="al.A multi-center randomized prospective study on the treatment of infant" exact="bronchiolitis" post="with interferon Î±1b nebulization [published correction appears in PLoS"/>
  <result pre="Immunol202011106110.3389/fimmu.2020.0106132574262 108.Dashti-KhavidakiSKhaliliHConsiderations for statin therapy in patients with COVID-19Pharmacotherapy202010.1002/phar.239732267560 109.Massachusetts" exact="General" post="Hospital COVID-19 Treatment Guidance Version 1.0. https://medtube.net/infectious-diseases/medical-documents/26086-covid19-treatment-guidelines-by-massachusetts-general-hospital. Accessed 17"/>
  <result pre="Infect20136729310110.1016/j.jinf.2013.04.01523665030 112.YuanSStatins may decrease the fatality rate of Middle East" exact="respiratory" post="syndrome infectionmBio201564e01120-1510.1128/mBio.01120-1526265720 113.DeDiegoMLNieto-TorresJLRegla-NavaJAJimenez-GuardeÃ±oJMFernandez-DelgadoRFettCet al.Inhibition of NF-ÎºB-mediated inflammation in severe"/>
  <result pre="112.YuanSStatins may decrease the fatality rate of Middle East respiratory" exact="syndrome" post="infectionmBio201564e01120-1510.1128/mBio.01120-1526265720 113.DeDiegoMLNieto-TorresJLRegla-NavaJAJimenez-GuardeÃ±oJMFernandez-DelgadoRFettCet al.Inhibition of NF-ÎºB-mediated inflammation in severe acute"/>
  <result pre="respiratory syndrome infectionmBio201564e01120-1510.1128/mBio.01120-1526265720 113.DeDiegoMLNieto-TorresJLRegla-NavaJAJimenez-GuardeÃ±oJMFernandez-DelgadoRFettCet al.Inhibition of NF-ÎºB-mediated inflammation in severe" exact="acute" post="respiratory syndrome coronavirus-infected mice increases survivalJ Virol201488291310.1128/JVI.02576-1324198408 114.ToturaALWhitmoreAAgnihothramSet al.Toll-like"/>
  <result pre="syndrome infectionmBio201564e01120-1510.1128/mBio.01120-1526265720 113.DeDiegoMLNieto-TorresJLRegla-NavaJAJimenez-GuardeÃ±oJMFernandez-DelgadoRFettCet al.Inhibition of NF-ÎºB-mediated inflammation in severe acute" exact="respiratory" post="syndrome coronavirus-infected mice increases survivalJ Virol201488291310.1128/JVI.02576-1324198408 114.ToturaALWhitmoreAAgnihothramSet al.Toll-like receptor"/>
  <result pre="infectionmBio201564e01120-1510.1128/mBio.01120-1526265720 113.DeDiegoMLNieto-TorresJLRegla-NavaJAJimenez-GuardeÃ±oJMFernandez-DelgadoRFettCet al.Inhibition of NF-ÎºB-mediated inflammation in severe acute respiratory" exact="syndrome" post="coronavirus-infected mice increases survivalJ Virol201488291310.1128/JVI.02576-1324198408 114.ToturaALWhitmoreAAgnihothramSet al.Toll-like receptor 3"/>
  <result pre="TRIF contributes to a protective innate immune response to severe" exact="acute" post="respiratory syndrome coronavirus infectionmBio201563e00638-1510.1128/mBio.00638-1526015500 115.SheahanTMorrisonTEFunkhouserWet al.MyD88 is required for"/>
  <result pre="contributes to a protective innate immune response to severe acute" exact="respiratory" post="syndrome coronavirus infectionmBio201563e00638-1510.1128/mBio.00638-1526015500 115.SheahanTMorrisonTEFunkhouserWet al.MyD88 is required for protection"/>
  <result pre="to a protective innate immune response to severe acute respiratory" exact="syndrome" post="coronavirus infectionmBio201563e00638-1510.1128/mBio.00638-1526015500 115.SheahanTMorrisonTEFunkhouserWet al.MyD88 is required for protection from"/>
  <result pre="coronavirus infectionmBio201563e00638-1510.1128/mBio.00638-1526015500 115.SheahanTMorrisonTEFunkhouserWet al.MyD88 is required for protection from lethal" exact="infection" post="with a mouse-adapted SARS-CoVPLoS Pathog2008412e100024010.1371/journal.ppat.100024019079579 116.YuanXDengYGuoXShangJZhuDLiuHAtorvastatin attenuates myocardial remodeling"/>
  <result pre="a mouse-adapted SARS-CoVPLoS Pathog2008412e100024010.1371/journal.ppat.100024019079579 116.YuanXDengYGuoXShangJZhuDLiuHAtorvastatin attenuates myocardial remodeling induced by" exact="chronic" post="intermittent hypoxia in rats: partly involvement of TLR-4/MYD88 pathwayBiochem"/>
  <result pre="SARS-CoVPLoS Pathog2008412e100024010.1371/journal.ppat.100024019079579 116.YuanXDengYGuoXShangJZhuDLiuHAtorvastatin attenuates myocardial remodeling induced by chronic intermittent" exact="hypoxia" post="in rats: partly involvement of TLR-4/MYD88 pathwayBiochem Biophys Res"/>
  <result pre="of ARBs, ACEIs and statins on clinical outcomes of COVID-19" exact="infection" post="among nursing home residentsJ Am Med Dir Assoc202010.1016/j.jamda.2020.06.01832674818 119.ChangYWeiWAngiotensin"/>
  <result pre="lung injuryNat Med200511887587910.1038/nm126716007097 122.ImaiYKubaKRaoSet al.Angiotensin-converting enzyme 2 protects from severe" exact="acute" post="lung failureNature2005436704711211610.1038/nature0371216001071 123.TikellisCBernardiSBurnsWCAngiotensin-converting enzyme 2 is a key modulator"/>
  <result pre="2 is a key modulator of the reninâ€&quot;angiotensin system in" exact="cardiovascular" post="and renal diseaseCurr Opin Nephrol Hypertens2011201626810.1097/MNH.0b013e328341164a21099686 124.ReynoldsHRAdhikariSPulgarinCet al.Reninâ€&quot;angiotensinâ€&quot;aldosterone system"/>
  <result pre="the risk of covid-19N Engl J Med2020382252431244010.1056/NEJMoa200692332356627 126.CurfmanGReninâ€&quot;angiotensinâ€&quot;aldosterone inhibitors and" exact="susceptibility to" post="and severity of COVID-19JAMA202010.1001/jama.2020.1140132558905 127.Bermejo-MartinJFKelvinDJEirosJMet al.Macrolides for the treatment"/>
  <result pre="severity of COVID-19JAMA202010.1001/jama.2020.1140132558905 127.Bermejo-MartinJFKelvinDJEirosJMet al.Macrolides for the treatment of severe" exact="respiratory" post="illness caused by novel H1N1 swine influenza viral strainsJ"/>
  <result pre="the treatment of severe respiratory illness caused by novel H1N1" exact="swine influenza" post="viral strainsJ Infect Dev Ctries2009315916110.3855/jidc.1819759469 128.ZhangYDaiJJianHet al.Effects of macrolides"/>
  <result pre="of severe respiratory illness caused by novel H1N1 swine influenza" exact="viral" post="strainsJ Infect Dev Ctries2009315916110.3855/jidc.1819759469 128.ZhangYDaiJJianHet al.Effects of macrolides on"/>
  <result pre="Immunol20196334334910.1111/1348-0421.12726)31283028 129.KawamuraKIchikadoKTakakiMet al.Adjunctive therapy with azithromycin for moderate and severe" exact="acute" post="respiratory distress syndrome: a retrospective, propensity score-matching analysis of"/>
  <result pre="129.KawamuraKIchikadoKTakakiMet al.Adjunctive therapy with azithromycin for moderate and severe acute" exact="respiratory" post="distress syndrome: a retrospective, propensity score-matching analysis of prospectively"/>
  <result pre="Microbiol Immunol Infect20195287287910.1016/j.jmii.2019.10.00131759853 131.AbramsEMRaissyHHEmerging therapies in the treatment of early" exact="childhood" post="wheezePediatr Allergy Immunol Pulmonol201932788010.1089/ped.2019.104331508261 132.ArabiYMDeebAMAl-HameedFet al.Macrolides in critically ill"/>
  <result pre="Pulmonol201932788010.1089/ped.2019.104331508261 132.ArabiYMDeebAMAl-HameedFet al.Macrolides in critically ill patients with Middle East" exact="respiratory" post="syndromeInt J Infect Dis20198118419010.1016/j.ijid.2019.01.04130690213 133.IshaquiAAKhanAHSulaimanSASet al.Assessment of efficacy of"/>
  <result pre="efficacy of oseltamivir-azithromycin combination therapy in prevention of Influenza-A (H1N1)pdm09" exact="infection" post="complications and rapidity of symptoms reliefExpert Rev Respir Med202014553354110.1080/17476348.2020.173018032053044"/>
  <result pre="Rev Respir Med202014553354110.1080/17476348.2020.173018032053044 134.SchoglerAKopfBSEdwardsMRet al.Novel antiviral properties of azithromycin in" exact="cystic fibrosis" post="airway epithelial cellsEur Respir J20154542843910.1183/09031936.0010201425359346 135.LeeNWongCKChanMCWet al.Anti-inflammatory effects of"/>
  <result pre="134.SchoglerAKopfBSEdwardsMRet al.Novel antiviral properties of azithromycin in cystic fibrosis airway" exact="epithelial" post="cellsEur Respir J20154542843910.1183/09031936.0010201425359346 135.LeeNWongCKChanMCWet al.Anti-inflammatory effects of adjunctive macrolide"/>
  <result pre="a randomized controlled trialAntivir Res2017144485610.1016/j.antiviral.2017.05.00828535933 136.RayWAMurrayKTHallKArbogastPGSteinCMAzithromycin and the risk of" exact="cardiovascular" post="deathN Engl J Med2012366201881189010.1056/NEJMoa100383322591294 137.DevauxCARolainJMColsonPet al.New insights on the"/>
  <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis202010.1093/cid/ciaa23732613227 139.SahraeiZShabaniMShokouhiSet al.Aminoquinolines"/>
  <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis202010.1093/cid/ciaa23732613227 139.SahraeiZShabaniMShokouhiSet al.Aminoquinolines against"/>
  <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)Clin Infect Dis202010.1093/cid/ciaa23732613227 139.SahraeiZShabaniMShokouhiSet al.Aminoquinolines against coronavirus"/>
  <result pre="syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis202010.1093/cid/ciaa23732613227 139.SahraeiZShabaniMShokouhiSet al.Aminoquinolines against coronavirus" exact="disease" post="2019 (COVID-19): chloroquine or hydroxychloroquineInt J Antimicrob Agents202055410594510.1016/j.ijantimicag.2020.10594532194152 140.ZhouDDaiSMTongQCOVID-19:"/>
  <result pre="a recommendation to examine the effect of hydroxychloroquine in preventing" exact="infection" post="and progressionJ Antimicrob Chemother20207571667167010.1093/jac/dkaa11432196083 141.Ben-ZviIKivitySLangevitzPShoenfeldYHydroxychloroquine: from malaria to autoimmunityClin"/>
  <result pre="hydroxychloroquine in preventing infection and progressionJ Antimicrob Chemother20207571667167010.1093/jac/dkaa11432196083 141.Ben-ZviIKivitySLangevitzPShoenfeldYHydroxychloroquine: from" exact="malaria" post="to autoimmunityClin Rev Allergy Immunol201242214515310.1007/s12016-010-8243-x21221847 142.BonamSRMullerSBayryJKlionskyDJAutophagy as an emerging"/>
  <result pre="143.TangWCaoZHanMet al.Hydroxychloroquine in patients with mainly mild to moderate coronavirus" exact="disease" post="2019: open label, randomised controlled trialBMJ2020369m184910.1136/bmj.m184932409561 144.GiudicessiJRNoseworthyPAFriedmanPAAckermanMJUrgent guidance for"/>
  <result pre="the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus" exact="disease" post="19 (COVID-19)Mayo Clin Proc202010.1016/j.mayocp.2020.03.02432359771 145.GelerisJSunYPlattJet al.Observational study of hydroxychloroquine"/>
  <result pre="by up to one third in hospitalised patients with severe" exact="respiratory" post="complications of COVID-19. 2020. https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19. Accessed 20 Jun 2020."/>
  <result pre="chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical"/>
  <result pre="diphosphate as adjunctive therapy for patients hospitalized with severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trialJAMA"/>
  <result pre="as adjunctive therapy for patients hospitalized with severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trialJAMA Netw"/>
  <result pre="Metab Toxicol201511111781179410.1517/17425255.2015.107639126239119 153.GendelmanOAmitalHBragazziNLWatadAChodickGContinuous hydroxychloroquine or colchicine therapy does not prevent" exact="infection" post="with SARS-CoV-2: insights from a large healthcare database analysisAutoimmun"/>
  <result pre="pneumoniaCytokine Growth Factor Rev202053384210.1016/j.cytogfr.2020.04.00232360420 158.ZhaoJZhaoJLeggeKPerlmanSAge-related increases in PGD(2) expression impair" exact="respiratory" post="DC migration, resulting in diminished T cell responses upon"/>
  <result pre="respiratory DC migration, resulting in diminished T cell responses upon" exact="respiratory" post="virus infection in miceJ Clin Investig2011121124921493010.1172/JCI5977722105170 159.TrabanelliSChevalierMFMartinez-UsatorreAet al.Tumour-derived PGD2"/>
  <result pre="DC migration, resulting in diminished T cell responses upon respiratory" exact="virus infection" post="in miceJ Clin Investig2011121124921493010.1172/JCI5977722105170 159.TrabanelliSChevalierMFMartinez-UsatorreAet al.Tumour-derived PGD2 and NKp30-B7H6"/>
  <result pre="migration, resulting in diminished T cell responses upon respiratory virus" exact="infection" post="in miceJ Clin Investig2011121124921493010.1172/JCI5977722105170 159.TrabanelliSChevalierMFMartinez-UsatorreAet al.Tumour-derived PGD2 and NKp30-B7H6"/>
  <result pre="and humansJ Clin Investig2008118124036404810.1172/JCI3626419033672 161.MindtBCFritzJHDuerrCUGroup 2 innate lymphoid cells in" exact="pulmonary" post="immunity and tissue homeostasisFront Immunol2018984010.3389/fimmu.2018.0084029760695 162.KupczykMKunaPTargeting the PGD2/CRTH2/DP1 signaling"/>
  <result pre="and tissue homeostasisFront Immunol2018984010.3389/fimmu.2018.0084029760695 162.KupczykMKunaPTargeting the PGD2/CRTH2/DP1 signaling pathway in" exact="asthma" post="and allergic disease: current status and future perspectivesDrugs201777121281129410.1007/s40265-017-0777-228612233 163.IshizukaTMatsuiTOkamotoYOhtaAShichijoMRamatroban"/>
  <result pre="a Mediator of Lymphopenia and a Therapeutic Target in COVID-19" exact="Disease" post="(June 18, 2020). Available at SSRN: https://ssrn.com/abstract=3633469. Accessed 8"/>
 </snippets>
</snippetsTree>
